Spots Global Cancer Trial Database for Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma

Official Title: A Phase II Placebo-controlled Intervention Trial of Oral Aspirin (ASA) as a UV Protectant in Vivo

Study ID: NCT04066725

Conditions

Melanoma (Skin)

Interventions

Aspirin 81 mg

Aspirin 325mg

Placebo oral tablet

Study Description

Brief Summary: This is a phase II placebo-controlled intervention trial assessing aspirin (ASA) as a UV protectant in patients at risk for melanoma.

Detailed Description: While melanoma risk is largely genetically determined, exposure to ultraviolet (UV) radiation in sunlight is the major environmental risk factor. Although sunscreen use can reduce melanoma risk 2-fold, its efficacy has been questioned, and most patients do not apply sunscreens properly. This study will evaluate the downstream effects of aspirin (ASA) in human blood and skin moles (nevi) following oral ingestion. We will determine if chronic ingestion of ASA can modulate UV-sensitivity of the skin, UV-induced damage in nevi, and PGE2 levels in blood and nevi.